APVO Aptevo: Forward P/S Multiple
The forward P/S dynamics, with GURU.Markets data illustrated on this chart, show that the current mark equals 2.90. The ADAPTIR patent portfolio limits biotech competition despite strict FDA oversight. Aptevo Therapeutics (APVO) focuses on developing targeted immunotherapy to combat tumors. The ecosystem retains patients in trials, while development is funded through partnerships with pharma behemoths.
APVO (Aptevo): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Aptevo Therapeutics|APVO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Aptevo|APVO - Company Debts|Debt to Book Capitalization Ratio Aptevo Therapeutics Inc.|APVO - Long-Term Debt|Company Current Liabilities Aptevo Therapeutics|Quick Liquidity Indicator aptevotherapeutics.com
- business earnings and investment ratios data:
APVO - Profit After Payment of Taxes|Projected Future Earnings Aptevo Therapeutics|APVO - Company Value to Net Income|Forward P/E Multiple Aptevo Therapeutics Inc.|APVO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics, Inc.|APVO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aptevo Therapeutics|APVO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months aptevotherapeutics.com|APVO - Earnings per share trend in current year|Earnings growth forecast for next year Aptevo Therapeutics
- sales volume and revenue information:
Summary company analytics:APVO (Aptevo)
For the biotech startup Aptevo Therapeutics (APVO), whose success depends on antibody test outcomes, the forward P/S ratio determines the asset's market value based on expected revenue. It is critical for investors to benchmark the projected P/S value against capital raising rates and development stages to timely identify business overvaluation or discover an entry point with minimal risk of fundamental impairment.
Competitor analysis
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Biosciences)|Market Cap to Expected Sales Ratio theratech.com|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc.)|Forward P/S Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio, Inc)|ZURA: Forward P/S Multiple|aTyr Pharma, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Adagene Inc.|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Forward Price-to-Revenue Multiple Equillium Bio EQ|Price-to-Projected Revenue Ratio Connect Biopharma CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx NV (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Adicet Bio Inc. (ACET)|Price-to-Projected Revenue Ratio celularity.com|Forward Price-to-Revenue Multiple inmunebio.com (INMB)|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics PLC (BRNS)|Market Cap to Expected Sales Ratio Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Akari Therapeutics, Plc (AKTX)|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Edesa|Price-to-Projected Revenue Ratio iBio, Inc.|Forward Price-to-Revenue Multiple carismatx.com (CARM)|Forward P/S Multiple XTLB|Forward Price-to-Revenue Multiple Bolt Bio BOLT|Forward P/S Multiple HCWB (HCW Biologics)|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
